Raymond Debbane

Insider Reports History

Reporting-owner location: New York, NY
Latest reporting-owner signature: /s/ Raymond Debbane
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Raymond Debbane

Form 4 holding Director

LEXICON PHARMACEUTICALS, INC.

Security class: Common Stock
Shares / value: 35,402,689
Estimated value: $55,228,194
Report date: 03 Jun 2026
Price: $1.56
Ownership: By Invus, L.P. and related parties

Form 4 holding Director

LEXICON PHARMACEUTICALS, INC.

Security class: Common Stock
Shares / value: 7,362,368
Estimated value: $11,485,294
Report date: 03 Jun 2026
Price: $1.56
Ownership: By Invus Public Equities, L.P. and related parties

Form 4 holding Director

LEXICON PHARMACEUTICALS, INC.

Security class: Common Stock
Shares / value: 5,451,204
Estimated value: $8,503,878
Report date: 03 Jun 2026
Price: $1.56
Ownership: By Invus US Partners, LLC and related parties

Form 4 holding Director

LEXICON PHARMACEUTICALS, INC.

Security class: Common Stock
Shares / value: 1,995,498
Estimated value: $3,112,976
Report date: 03 Jun 2026
Price: $1.56
Ownership: Direct

Form 4 holding Director

LEXICON PHARMACEUTICALS, INC.

Security class: Common Stock
Shares / value: 1,538,462
Estimated value: $2,400,000
Report date: 03 Jun 2026
Price: $1.56
Ownership: By Avicenna Life Sci Master Fund LP and related parties

Form 4 holding Former Director

WW INTERNATIONAL, INC.

Security class: Common Stock
Shares / value: 134,387
Estimated value: $945,614
Report date: 09 May 2023
Price: $7.04
Ownership: Direct

Form 4 holding Director

LEXICON PHARMACEUTICALS, INC.

Security class: Restricted Stock Units
Shares / value: 0
Estimated value: $96,442
Report date: 03 Jun 2026
Price: $2.62
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

LEXICON PHARMACEUTICALS, INC.

Security class: Stock Option (Right to Buy)
Shares / value: 43,478
Estimated value
Report date: 01 May 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Raymond Debbane

4 LXRX

LEXICON PHARMACEUTICALS, INC.

Report period: 03 Jun 2026
Transactions: 2
Transaction value: $0
Accepted by SEC: 04 Jun 2026, 16:09
Role: Director
Next action: Open filing details

4 LXRX

LEXICON PHARMACEUTICALS, INC.

Report period: 01 May 2026
Transactions: 2
Transaction value: $0
Accepted by SEC: 04 May 2026, 16:09
Role: Director
Next action: Open filing details

4 LXRX

LEXICON PHARMACEUTICALS, INC.

Report period: 25 Feb 2026
Transactions: 1
Transaction value: +$2,980
Accepted by SEC: 27 Feb 2026, 08:33
Role: Director
Next action: Open filing details

4 LXRX

LEXICON PHARMACEUTICALS, INC.

Report period: 23 Feb 2026
Transactions: 1
Transaction value: +$147,000
Accepted by SEC: 25 Feb 2026, 07:00
Role: Director
Next action: Open filing details

4 LXRX

LEXICON PHARMACEUTICALS, INC.

Report period: 19 Feb 2026
Transactions: 2
Transaction value: +$219,755
Accepted by SEC: 23 Feb 2026, 07:49
Role: Director
Next action: Open filing details

4 LXRX

LEXICON PHARMACEUTICALS, INC.

Report period: 13 Feb 2026
Transactions: 3
Transaction value: +$352,889
Accepted by SEC: 18 Feb 2026, 16:30
Role: Director
Next action: Open filing details

4 LXRX

LEXICON PHARMACEUTICALS, INC.

Report period: 03 Jun 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 03 Jun 2025, 16:20
Role: Director
Next action: Open filing details

4 LXRX

LEXICON PHARMACEUTICALS, INC.

Report period: 13 May 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 13 May 2025, 17:48
Role: Director
Next action: Open filing details

4 LXRX

LEXICON PHARMACEUTICALS, INC.

Report period: 13 May 2024
Transactions: 2
Transaction value: $0
Accepted by SEC: 13 May 2024, 16:02
Role: Director
Next action: Open filing details

4 LXRX

LEXICON PHARMACEUTICALS, INC.

Report period: 28 Apr 2024
Transactions: 2
Transaction value: $0
Accepted by SEC: 29 Apr 2024, 16:17
Role: Director
Next action: Open filing details

4 LXRX

LEXICON PHARMACEUTICALS, INC.

Report period: 10 Oct 2023
Transactions: 3
Transaction value: +$1,103,957
Accepted by SEC: 12 Oct 2023, 16:01
Role: Director
Next action: Open filing details

4 LXRX

LEXICON PHARMACEUTICALS, INC.

Report period: 21 May 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 22 May 2023, 16:03
Role: Director
Next action: Open filing details

4 WW

WW INTERNATIONAL, INC.

Report period: 09 May 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 11 May 2023, 16:12
Role: Former Director
Next action: Open filing details

4 LXRX

LEXICON PHARMACEUTICALS, INC.

Report period: 28 Apr 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 28 Apr 2023, 16:22
Role: Director
Next action: Open filing details

4 WW

WW INTERNATIONAL, INC.

Report period: 03 Apr 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 05 Apr 2023, 16:05
Role: Director
Next action: Open filing details

4 WW

WW INTERNATIONAL, INC.

Report period: 02 Jan 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 04 Jan 2023, 15:22
Role: Director
Next action: Open filing details

4 WW

WW INTERNATIONAL, INC.

Report period: 10 Nov 2022
Transactions: 1
Transaction value: +$320,055
Accepted by SEC: 15 Nov 2022, 16:26
Role: Director
Next action: Open filing details

4 WW

WW INTERNATIONAL, INC.

Report period: 03 Oct 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 05 Oct 2022, 17:27
Role: Director
Next action: Open filing details

4 LXRX

LEXICON PHARMACEUTICALS, INC.

Report period: 01 Aug 2022
Transactions: 1
Transaction value: +$2,456,500
Accepted by SEC: 01 Aug 2022, 16:13
Role: Director
Next action: Open filing details

4 WW

WW INTERNATIONAL, INC.

Report period: 04 Jul 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 06 Jul 2022, 16:31
Role: Director
Next action: Open filing details

4 LXRX

LEXICON PHARMACEUTICALS, INC.

Report period: 21 May 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 23 May 2022, 16:14
Role: Director
Next action: Open filing details

4 LXRX

LEXICON PHARMACEUTICALS, INC.

Report period: 30 Apr 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 02 May 2022, 16:14
Role: Director
Next action: Open filing details

4 WW

WW INTERNATIONAL, INC.

Report period: 04 Apr 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 06 Apr 2022, 16:15
Role: Director
Next action: Open filing details

4 WW

WW INTERNATIONAL, INC.

Report period: 03 Jan 2022
Transactions: 1
Transaction value: +$18,746
Accepted by SEC: 05 Jan 2022, 15:16
Role: Director
Next action: Open filing details

4 WW

WW INTERNATIONAL, INC.

Report period: 04 Oct 2021
Transactions: 1
Transaction value: +$18,742
Accepted by SEC: 06 Oct 2021, 16:07
Role: Director
Next action: Open filing details

4 WW

WW INTERNATIONAL, INC.

Report period: 05 Jul 2021
Transactions: 1
Transaction value: +$18,744
Accepted by SEC: 07 Jul 2021, 16:20
Role: Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .